Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Receives Approval to Commercialize New Thyroid Test in New York, Pennsylvania

NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that it has received approval to launch its ThyGeNext assay in New York and Pennsylvania, allowing the firm to sell the thyroid cancer detection assay to physicians in the two states.  

According to Interpace, the Pennsylvania approval is final, while the New York state approval is conditional — final approval in New York with depend on Interpace's submission of additional information to state regulators. Interpace said it will sell ThyGeNext in New York and Pennsylvania in combination with its ThyraMir microRNA gene expression classifier.

The ThyGeNext panel — which was launched in May to build on the company's ThyGenX panel — uses next-generation sequencing to identify more than 150 genomic alterations associated with papillary, medullary, and follicular thyroid carcinomas. The tool includes multiple additional molecular markers, gene mutations, and RNA fusions than Interpace's previous thyroid cancer diagnostic assays including PTEN, ALK, TERT, RET, and NTRK, among others, the firm said. The new assay also interrogates a more comprehensive set of indicators to identify malignant or benign nodules, as well as to confirm cancer aggressiveness and other characteristics.

In June, Interpace announced that Blue Cross Blue Shield began covering its ThyGenX and ThyraMir gene panels in Florida.

In addition to its thyroid cancer line, Interpace will transition its pancreatic cancer assays to an NGS platform for testing biliary strictures and solid pancreatic lesions.

"We are pleased that we are now able to sell our newest thyroid product in these key markets representing significant opportunity for us, but also for physicians and their patients in these states as well," Interpace President and CEO Jack Stover said in a statement.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.